Precision Therapeutics in Profound Autism

Tuesday, May 6, 9am-3:30pm

Register to attend - tickets only $25: https://AdvancesinAutism2025.eventbrite.com

International studies led by the Director of the Seaver Autism Center, Joseph D. Buxbaum, PhD, MSc and colleagues, have identified nearly 200 genes that, if changed, strongly contribute to autism. Researchers are now shifting their focus on treatments for autism to look at genetically determined subtypes of autism and consider treatments that are tailored to the genetic subtype. This approach, called precision therapeutics, has revolutionized cancer treatment, and will revolutionize the treatment of profound autism.